Oncopeptides AB (publ)

Oncopeptides AB (publ) is a biotech company that researches, develops, and commercializes targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate with an alkylating payload for adult patients with multiple myeloma. The company's PDC platform uses a peptide carrier and a cytotoxic payload to exploit altered cancer cell metabolism, and it also offers OPD5, OPDC3, and Gliopep for hematological or solid tumors and glioblastoma, as well as a Small Polypeptide based Killer Engagers (SPiKE) platform. Incorporated in 2000, it is headquartered in Stockholm, Sweden.